TY - JOUR
T1 - Prognostic and predictive factors in prostate cancer
T2 - Historical perspectives and recent international consensus initiatives
AU - Srigley, John R.
AU - Amin, Mahul
AU - Boccon-Gibod, Liliane
AU - Egevad, Lars
AU - Epstein, Jonathan I.
AU - Humphrey, Peter A.
AU - Mikuz, Gregor
AU - Newling, Don
AU - Nilsson, Sten
AU - Sakr, Wael
AU - Wheeler, Thomas M.
AU - Montironi, Rodolfo
PY - 2005/5
Y1 - 2005/5
N2 - An understanding of prognosis in cancer medicine is important for patient care, research and cancer control programs. In prostate cancer, prognostic (predictive) factors are particularly important given the marked heterogeneity of this disease at clinical, morphologic and biomolecular levels. Clinical stage and histologic grade have historically played major roles in defining heterogeneity in prostate cancer. More recently, serum prostate-specific antigen measurement has assumed a significant prognostic role. Over the last two decades there has been an explosion of research into biomarkers, many of which have been purported to have prognostic significance. In this paper we present an overview of the various consensus initiatives that have transpired over the last dozen years. Criteria for evaluating prognostic factors and classifications of predictive factors have emerged that have proven useful and advanced our understanding of the biology of prostate cancer. The results of these consensus initiatives form a foundation on which the current international consultation on prognosis (prediction) in prostate cancer is built. Advances in our understanding of the new and promising prognostic factors will require a more rigorous evidence-based approach to the analysis of published studies. Furthermore, appropriate mathematical models for the analysis of the multiple factors that influence a prognostic system will have to be employed.
AB - An understanding of prognosis in cancer medicine is important for patient care, research and cancer control programs. In prostate cancer, prognostic (predictive) factors are particularly important given the marked heterogeneity of this disease at clinical, morphologic and biomolecular levels. Clinical stage and histologic grade have historically played major roles in defining heterogeneity in prostate cancer. More recently, serum prostate-specific antigen measurement has assumed a significant prognostic role. Over the last two decades there has been an explosion of research into biomarkers, many of which have been purported to have prognostic significance. In this paper we present an overview of the various consensus initiatives that have transpired over the last dozen years. Criteria for evaluating prognostic factors and classifications of predictive factors have emerged that have proven useful and advanced our understanding of the biology of prostate cancer. The results of these consensus initiatives form a foundation on which the current international consultation on prognosis (prediction) in prostate cancer is built. Advances in our understanding of the new and promising prognostic factors will require a more rigorous evidence-based approach to the analysis of published studies. Furthermore, appropriate mathematical models for the analysis of the multiple factors that influence a prognostic system will have to be employed.
KW - Historical aspects
KW - Prediction
KW - Previous consensus initiatives
KW - Prognostic factors
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=22144463914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144463914&partnerID=8YFLogxK
U2 - 10.1080/03008880510030914
DO - 10.1080/03008880510030914
M3 - Article
C2 - 16019756
AN - SCOPUS:22144463914
SN - 0300-8886
VL - 39
SP - 8
EP - 19
JO - Scandinavian Journal of Urology and Nephrology, Supplement
JF - Scandinavian Journal of Urology and Nephrology, Supplement
IS - 216
ER -